Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Stroke. 2011 Aug 25;42(11):3281–3283. doi: 10.1161/STROKEAHA.111.626507

Table 1.

Baseline characteristics of poststroke patients in the placebo, escitalopram, or problem-solving therapy groups

Placebo (n=33) Escitalopram (n=34) Problem-Solving Therapy (n=41) Test Results P value
Age, mean(SD), y 67.5 (12.5) 63.7 (13.9) 66.1 (10.6) Kruskal-Wallis (χ2 (2)=1.90) 0.3870
Male, % 63.6 61.8 48.8 Fisher’s exact 0.3825
Married, % 51.5 55.9 51.2 Fisher’s exact 0.9128
Previous history of depression, % 0 8.8 2.4 Fisher’s exact 0.1942
Education, mean (SD), y 13.3 (3.2) 13.9 (2.6) 14.0 (3.0) Kruskal-Wallis (χ2 (2)=0.62) 0.7351
Stroke characteristics, %
 Large-artery atherosclerosis 30.3 29.4 29.3 Fisher’s exact 1.000
 Small-artery occlusion 30.3 20.6 34.1 Fisher’s exact 0.4117
 Cardioembolism/Other 30.3 44.1 29.3 Fisher’s exact 0.3627
Left-side lesions 45.5 55.9 34.1 Fisher’s exact 0.1665